Metabolic-associated fatty liver disease increases the risk of end-stage renal disease in patients with biopsy-confirmed diabetic nephropathy: a propensity-matched cohort study.

Yutong ZouLijun ZhaoJunlin ZhangYiting WangYucheng WuHonghong RenTingli WangYuancheng ZhaoHuan XuLin LiNanwei TongFang Liu

Published in: Acta diabetologica (2022)

MAFLD increases the risk of incident ESRD in patients with biopsy-proven DN. Further research is needed to determine whether treatment targeting MAFLD improves the prognosis of DN.

Keyphrases

end stage renal disease
chronic kidney disease
diabetic nephropathy
peritoneal dialysis
ultrasound guided
fine needle aspiration
cardiovascular disease
cancer therapy
combination therapy
drug delivery
type diabetes
replacement therapy